文献速递淋巴瘤

在原发性中枢神经系统淋巴瘤中以NGR-hTNF提高R-CHOP抗肿瘤活性:2期试验最终结果

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
PubMed 文献 · Blood Adv · 2020-01-01

这项2期试验评估NGR-hTNF联合R-CHOP治疗对以大剂量甲氨蝶呤为基础化疗复发/难治的原发性中枢神经系统淋巴瘤患者的活性与安全性,主要终点总缓解率为75%(95%CI 59%-91%),其中完全缓解11例;中位随访21个月时5例无复发、6例存活;治疗耐受良好,未出现意外毒性、减量或中断。

要点

  • NGR-hTNF联合R-CHOP在复发/难治PCNSL中确认肿瘤缓解21例(75%;95%CI 59%-91%),完全缓解11例。
  • 中位随访21个月(范围14-31)时,5例保持无复发,6例存活。
  • 治疗耐受良好,未出现意外毒性、减量或中断。

核心结论

  • NGR-hTNF联合R-CHOP在对大剂量甲氨蝶呤为基础化疗复发/难治的PCNSL患者中具有活性,确认肿瘤缓解21例(75%;95%CI 59%-91%),其中完全缓解11例。
  • NGR-hTNF/R-CHOP的活性与肿瘤血管周细胞和内皮细胞中CD13的表达一致。
  • 血浆嗜铬粒蛋白A高水平与质子泵抑制剂使用及较低缓解率相关,提示基于TNF的治疗期间应避免这些药物。
  • 作者认为对这一中枢神经系统淋巴瘤创新方法需进一步研究。

研究设计与样本

  • 2期试验,纳入对大剂量甲氨蝶呤为基础化疗复发/难治的PCNSL患者。
  • 样本量28例被认为足以证明总缓解率从30%提高到50%;若记录到≥12例缓解则判定NGR-hTNF/R-CHOP具有活性。
  • 主要终点为总缓解率。
  • 试验注册号为EudraCT: 2014-001532-11。

主要发现

  • 确认肿瘤缓解21例(75%;95%CI 59%-91%),其中完全缓解11例。
  • 21例缓解患者中17例接受巩固治疗(ASCT、WBRT和/或来那度胺维持)。
  • 中位随访21个月(范围14-31)时,5例保持无复发,6例存活。
  • 治疗耐受良好,未出现意外毒性、减量或中断。
  • 血浆嗜铬粒蛋白A高水平与质子泵抑制剂使用及较低缓解率相关。

关键数值与推荐

  • 样本量28例被认为足以证明总缓解率从30%提高到50%。
  • 若记录到≥12例缓解则判定NGR-hTNF/R-CHOP具有活性。
  • 确认肿瘤缓解21例(75%;95%CI 59%-91%),完全缓解11例。
  • 中位随访21个月(范围14-31)时,5例保持无复发,6例存活。

临床怎么用

  • 作者建议基于TNF的治疗期间应避免质子泵抑制剂,因其与血浆嗜铬粒蛋白A高水平及较低缓解率相关。
  • 作者认为对这一中枢神经系统淋巴瘤创新方法需进一步研究。

局限性

  • 作者认为对这一中枢神经系统淋巴瘤创新方法需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma [PCNSL]) is an exception because of the low CNS bioavailability of related drugs. NGR-human tumor necrosis factor (NGR-hTNF) targets CD13+ vessels, enhances vascular permeability and CNS access of anticancer drugs, and provides the rationale for the treatment of PCNSL with R-CHOP. Herein, we report activity and safety of R-CHOP preceded by NGR-hTNF in patients with PCNSL relapsed/refractory to high-dose methotrexate-based chemotherapy enrolled in a phase 2 trial. Overall response rate (ORR) was the primary endpoint. A sample size of 28 patients was considered necessary to demonstrate improvement from 30% to 50% ORR. NGR-hTNF/R-CHOP would be declared active if ≥12 responses were recorded. Treatment was well tolerated; there were no cases of unexpected toxicities, dose reductions or interruptions. NGR-hTNF/R-CHOP was active, with confirmed tumor response in 21 patients (75%; 95% confidence interval, 59%-91%), which was complete in 11. Seventeen of the 21 patients with response to treatment received consolidation (ASCT, WBRT, and/or lenalidomide maintenance). At a median follow-up of 21 (range, 14-31) months, 5 patients remained relapse-free and 6 were alive. The activity of NGR-hTNF/R-CHOP is in line with the expression of CD13 in both pericytes and endothelial cells of tumor vessels. High plasma levels of chromogranin A, an NGR-hTNF inhibitor, were associated with proton pump inhibitor use and a lower remission rate, suggesting that these drugs should be avoided during TNF-based therapy. Further research on this innovative approach to CNS lymphomas is warranted. The trial was registered as EudraCT: 2014-001532-11.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ferreri AJM, Calimeri T, Ponzoni M, et al. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. Blood Adv. 2020. PMID: 32766857. doi:10.1182/bloodadvances.2020002270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。